Search results
Results from the WOW.Com Content Network
In a medicine that is administered periodically, the trough level should be measured just before the administration of the next dose in order to avoid overdosing. [3] A trough level is contrasted with a "peak level" (C max), which is the highest level of the medicine in the body, and the "average level", which is the mean level over time. It is ...
Serum vancomycin levels may be monitored in an effort to reduce side effects, [27] but the value of such monitoring has been questioned. [28] Peak and trough levels are usually monitored, and for research purposes the area under the concentration curve is also sometimes used. [29] Toxicity is best monitored by looking at trough values. [29]
Peak-to-trough ratio in pharmacokinetics is the ratio of peak (C max) and trough (C min) levels of a drug over its dosing interval (τ) at steady state.. Peak-to-trough ratio (PTR), also known as peak-to-trough variation or peak-to-trough fluctuation, is a parameter in pharmacokinetics which is defined as the ratio of C max (peak) concentration and C min (trough) concentration over a dosing ...
C max is the opposite of C min, which is the minimum (or trough) concentration that a drug achieves after dosing.The related pharmacokinetic parameter t max is the time at which the C max is observed.
The number of time points available in order to perform a successful NCA analysis should be enough to cover the absorption, distribution and elimination phase to accurately characterize the drug. Beyond AUC exposure measures, parameters such as Cmax (maximum concentration), Tmax (time to maximum concentration), CL and Vd can also be reported ...
That immediately gets the drug's concentration in the body up to the therapeutically-useful level. First day: 1000 mg; the body clears 100 mg, leaving 900 mg. On the second day, the patient takes 100 mg, bringing the level back to 1000 mg; the body clears 100 mg overnight, still leaving 900 mg, and so forth.
May be more narrow-spectrum than vancomycin, resulting in less bowel microbiota alteration. [9] Nausea (11%), vomiting, and abdominal pain. [10] Bactericidal in susceptible organisms such as C. difficile by inhibiting RNA polymerase, thereby inhibiting protein synthesis. [10] Monobactams; Aztreonam: Azactam: Gram-negative bacteria
Narrow-spectrum antibiotics have low propensity to induce bacterial resistance and are less likely to disrupt the microbiome (normal microflora). [3] On the other hand, indiscriminate use of broad-spectrum antibiotics may not only induce the development of bacterial resistance and promote the emergency of multidrug-resistant organisms, but also cause off-target effects due to dysbiosis.